First Header Logo Second Header Logo

Connection

Michael Shapiro to Cholesterol, LDL

This is a "connection" page, showing publications Michael Shapiro has written about Cholesterol, LDL.
Connection Strength

4.471
  1. Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23; 28(8):816-822.
    View in: PubMed
    Score: 0.661
  2. Wójcik C, Shapiro MD. Translating AHA/ACC cholesterol guidelines into meaningful risk reduction. J Fam Pract. 2019 05; 68(4):206;210;212;214;217;221B.
    View in: PubMed
    Score: 0.619
  3. Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 02 19; 8(4):e010932.
    View in: PubMed
    Score: 0.610
  4. Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. J Clin Lipidol. 2017 May - Jun; 11(3):667-673.
    View in: PubMed
    Score: 0.533
  5. Mahmood T, Miles JR, Minnier J, Tavori H, DeBarber AE, Fazio S, Shapiro MD. Effect of PCSK9 inhibition on plasma levels of small dense low density lipoprotein-cholesterol and 7-ketocholesterol. J Clin Lipidol. 2024; 18(1):e50-e58.
    View in: PubMed
    Score: 0.211
  6. Shapiro MD, Taub PR, Louie MJ, Lei L, Ballantyne CM. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 Aug; 378:117182.
    View in: PubMed
    Score: 0.206
  7. Rikhi R, Hammoud A, Ashburn N, Snavely AC, Michos ED, Chevli P, Tsai MY, Herrington D, Shapiro MD. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2022 Dec; 363:102-108.
    View in: PubMed
    Score: 0.196
  8. Shapiro MD. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving. Circulation. 2022 Oct 11; 146(15):1120-1122.
    View in: PubMed
    Score: 0.195
  9. Board C, Kelly MS, Shapiro MD, Dixon DL. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. J Cardiovasc Pharmacol. 2020 05; 75(5):410-420.
    View in: PubMed
    Score: 0.166
  10. Mahmood T, Shapiro MD. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Curr Opin Cardiol. 2019 09; 34(5):519-525.
    View in: PubMed
    Score: 0.158
  11. Duell PB, Gidding SS, Andersen RL, Knickelbine T, Anderson L, Gianos E, Shrader P, Kindt I, O'Brien EC, McCann D, Hemphill LC, Ahmed CD, Martin SS, Larry JA, Ahmad ZS, Kullo IJ, Underberg JA, Guyton J, Thompson P, Wilemon K, Roe MT, Rader DJ, Cuchel M, Linton MF, Shapiro MD, Moriarty PM, Knowles JW. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. 2019 10; 289:85-93.
    View in: PubMed
    Score: 0.158
  12. Warden BA, Minnier J, Watts GF, Fazio S, Shapiro MD. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. J Clin Lipidol. 2019 Jul - Aug; 13(4):580-585.
    View in: PubMed
    Score: 0.155
  13. Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
    View in: PubMed
    Score: 0.139
  14. Shapiro MD, Fazio S. Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. Nat Rev Cardiol. 2017 06; 14(6):319-320.
    View in: PubMed
    Score: 0.135
  15. Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains. Curr Atheroscler Rep. 2015 Apr; 17(4):499.
    View in: PubMed
    Score: 0.117
  16. Masrouri S, Tamehri Zadeh SS, Shapiro MD, Khalili D, Hadaegh F. Impact of optimal cholesterol levels on subclinical atherosclerosis in the absence of risk factors in young adults. Atherosclerosis. 2024 Jun; 393:117520.
    View in: PubMed
    Score: 0.054
  17. Miles J, Scotti A, Castagna F, Kuno T, Leone PP, Coisne A, Ludwig S, Lavie CJ, Joshi PH, Latib A, Garcia MJ, Rodriguez CJ, Shapiro MD, Virani SS, Slipczuk L. Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort. Circulation. 2024 Feb 06; 149(6):417-426.
    View in: PubMed
    Score: 0.053
  18. de Ferranti SD, Shrader P, Linton MF, Knowles JW, Hudgins LC, Benuck I, Kindt I, O'Brien EC, Peterson AL, Ahmad ZS, Clauss S, Duell PB, Shapiro MD, Wilemon K, Gidding SS, Neal W. Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. J Pediatr. 2021 02; 229:70-77.
    View in: PubMed
    Score: 0.043
  19. Ahmad ZS, Andersen RL, Andersen LH, O'Brien EC, Kindt I, Shrader P, Vasandani C, Newman CB, deGoma EM, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Kullo IJ, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016 Sep-Oct; 10(5):1223-9.
    View in: PubMed
    Score: 0.032
  20. deGoma EM, Ahmad ZS, O'Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.